Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SLC2A1 | P11166 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.41 |
| ▸ | VNN1 | O95497 | 1/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14419576 | 0.90 | SLC2A1 (0.45) | MRGPRX4MAPTLMNASLC2A1KDM4E | |
| SCHEMBL12328443 | 0.88 | PTGDR2 (0.54) | MRGPRX4MAPTSLC2A1PTGDR2 | |
| SCHEMBL12328442 | 0.87 | POLB (0.49) | MRGPRX4MAPTLMNAMEN1KMT2A | |
| SCHEMBL12955412 | 0.81 | KCNH2 (0.41) | S1PR1S1PR3 | |
| SCHEMBL12328445 | 0.79 | TMPRSS4 (0.50) | MAPTLMNAKDM4EMEN1RECQL | |
| SCHEMBL14419687 | 0.78 | SLC2A1 (0.46) | MRGPRX4MAPTLMNASLC2A1KDM4E | |
| SCHEMBL13715572 | 0.77 | SLC2A1 (0.53) | MAPTLMNASLC2A1 | |
| SCHEMBL11314652 | 0.77 | TSHR (0.51) | MAPTLMNAMEN1KMT2AMRGPRX1 | |
| SCHEMBL5325030 | 0.77 | PTGDR2 (0.57) | MRGPRX4MAPTSLC2A1PTGDR2 | |
| SCHEMBL5325241 | 0.77 | SLC2A1 (0.52) | MRGPRX4MAPTSLC2A1PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7569723-B2 | Benzoic acid derivatives as non nucleoside reverse-transcriptase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-08-04 | — | — | US | disclosed |
| US-20080114068-A1 | BENZOIC ACID DERIVATIVES AS NON NUCLEOSIDE REVERSE-TRANSCRIPTASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080114068-A1 | BENZOIC ACID DERIVATIVES AS NON NUCLEOSIDE REVERSE-TRANSCRIPTASE INHIBITORS | POLR2A, POLR1A, RTF1 | MRGPRX4 2791/4885MAPT 2396/4885LMNA 2692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.